Margit Mahlapuu
Directeur Général chez ScandiCure AB
Provenance du réseau au premier degré de Margit Mahlapuu
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
University of Gothenburg
35
| College/University | Other Consumer Services | 35 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.
8
| Subsidiary | Miscellaneous Commercial Services | 8 |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.
7
| Extinct | Miscellaneous Commercial Services | 7 |
Sixera Pharma AB
 Sixera Pharma AB Pharmaceuticals: GenericHealth Technology Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.
5
| Holding Company | Pharmaceuticals: Generic | 5 |
Pergamum AB
 Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
ScandiCure AB
 ScandiCure AB Pharmaceuticals: MajorHealth Technology ScandiCure AB develops anti-diabetic drug based on small molecule antagonists of a novel key mediator. The company was founded by Margit Mahlapuu on August 8, 2016 and is headquartered in Göteborg, Sweden.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Margit Mahlapuu via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| University of Lund | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal Comptroller/Controller/Auditor Corporate Officer/Principal | |
| University of Uppsala | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Chairman Chief Tech/Sci/R&D Officer | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member | |
Oncorena Holding AB
 Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chairman Director/Board Member | |
Sahlgrenska Universitetssjukhuset
 Sahlgrenska Universitetssjukhuset Hospital/Nursing ManagementHealth Services Sahlgrenska Universitetssjukhuset engages in the provision of basic and emergency medical care. It offers specialized care, pediatrics, transplant activity, treatment of cardiovascular diseases, immunology, and vaccine research. Its hospital provides an infrastructure necessary for teaching and research. The company was founded on January 1, 1997 and is based in Gothenburg, Sweden. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Chief Operating Officer | |
| RECIPHARM AB (PUBL) | Biotechnology | Director/Board Member Director of Finance/CFO Founder | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member | |
| Royal Institute of Technology | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
Cormorant Pharmaceuticals AB
 Cormorant Pharmaceuticals AB BiotechnologyHealth Technology Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Biomatcell AB
 Biomatcell AB BiotechnologyHealth Technology Biomatcell AB operates as a holding company that commercializes inventions in the fields of biomaterial science and cell therapy by licensing its inventions and creating spin-off companies. It develops three-dimensional biomaterial scaffold geometries in bioactive ceramics and metals. It markets products and services based on research in the field of biomaterials and stem cells and patenting new ideas in the same area. The company was founded on May 11, 2004 and is headquartered in Gothenburg, Sweden. | Biotechnology | Chairman Director of Finance/CFO Corporate Officer/Principal | |
BONE SUPPORT AB
 BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | Medical Specialties | Director of Finance/CFO Director/Board Member Director/Board Member | |
| BONESUPPORT HOLDING AB | Medical Specialties | Director of Finance/CFO Director/Board Member Director/Board Member | |
EffRx Pharmaceuticals SA
 EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Pharmaceuticals: Other | Director/Board Member Chairman Director/Board Member | |
| CERENO SCIENTIFIC AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member Founder | |
| TOLERANZIA AB | Biotechnology | Director/Board Member Founder Chairman | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer Chief Executive Officer | |
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Founder Chairman Director/Board Member | |
| FLERIE INVEST AB | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investment Managers | Director of Investments Consultant / Advisor | |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Investment Managers | Private Equity Investor Private Equity Investor | |
InDex Diagnostics AB
 InDex Diagnostics AB Pharmaceuticals: MajorHealth Technology Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB manufactures pharmaceutical products. The company is based in Solna, Sweden. Peter Hakim Zerhouni has been the CEO of the Swedish company since 2015. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Airsonett Holding AB | Corporate Officer/Principal Director/Board Member | ||
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NorthX Biologics Matfors AB
 NorthX Biologics Matfors AB BiotechnologyHealth Technology NorthX Biologics Matfors AB is a biologics company that specializes in high-quality protein production and DNA manufacturing. The company is based in Matfors, Sweden, and has subsidiaries in Sweden. The Swedish company offers comprehensive cell banking services, including master cell bank production, GMP cell banking, and cell bank characterization, ensuring quality and compliance for biological products. The company also provides premium plasmid DNA services, offering GMP, High Quality, and Research Grade plasmids for gene therapy, cell therapy, molecular biology research, and clinical applications. The company was founded in 1963, and Janet Hoogstraate has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Chairman | |
| Pergasus AB | Director/Board Member Director/Board Member | ||
| PROMIMIC AB | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Chairman Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member | |
Buzzard Pharmaceuticals AB
 Buzzard Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Medical/Nursing Services | Chairman Director/Board Member | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| STAYBLE THERAPEUTICS AB | Pharmaceuticals: Major | Founder Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Suède | 46 |
| Etats-Unis | 3 |
| Royaume-Uni | 2 |
| Suisse | 2 |
| Pays-Bas | 2 |
Sectorielle
| Health Technology | 35 |
| Consumer Services | 5 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 3 |
Opérationnelle
| Director/Board Member | 403 |
| Corporate Officer/Principal | 148 |
| Chairman | 114 |
| Chief Executive Officer | 65 |
| Independent Dir/Board Member | 57 |
Relations les plus connectées
- Bourse
- Insiders
- Margit Mahlapuu
- Connexions Sociétés
